191 related articles for article (PubMed ID: 16940800)
21. Norcantharidin analogues: synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition.
Hill TA; Stewart SG; Gordon CP; Ackland SP; Gilbert J; Sauer B; Sakoff JA; McCluskey A
ChemMedChem; 2008 Dec; 3(12):1878-92. PubMed ID: 19025735
[TBL] [Abstract][Full Text] [Related]
22. Induction of apoptosis on carcinoma cells by two synthetic cantharidin analogues.
Kok SH; Chui CH; Lam WS; Chen J; Tang JC; Lau FY; Cheng GY; Wong RS; Chan AS
Int J Mol Med; 2006 Jan; 17(1):151-7. PubMed ID: 16328024
[TBL] [Abstract][Full Text] [Related]
23. The protein phosphatase inhibitor cantharidin alters vascular endothelial cell permeability.
Knapp J; Bokník P; Lüss I; Huke S; Linck B; Lüss H; Müller FU; Müller T; Nacke P; Noll T; Piper HM; Schmitz W; Vahlensieck U; Neumann J
J Pharmacol Exp Ther; 1999 Jun; 289(3):1480-6. PubMed ID: 10336542
[TBL] [Abstract][Full Text] [Related]
24. In vitro anti-proliferation/cytotoxic activity of cantharidin (Spanish Fly) and related derivatives.
Williams LA; Möller W; Merisor E; Kraus W; Rösner H
West Indian Med J; 2003 Mar; 52(1):10-3. PubMed ID: 12806747
[TBL] [Abstract][Full Text] [Related]
25. Phoslactomycin targets cysteine-269 of the protein phosphatase 2A catalytic subunit in cells.
Teruya T; Simizu S; Kanoh N; Osada H
FEBS Lett; 2005 Apr; 579(11):2463-8. PubMed ID: 15848189
[TBL] [Abstract][Full Text] [Related]
26. Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
Ren Y; Kinghorn AD
Bioorg Med Chem; 2021 Feb; 32():116012. PubMed ID: 33454654
[TBL] [Abstract][Full Text] [Related]
27. Apoptogenic activity of a synthetic cantharimide in leukaemia: implication on its structural activity relationship.
Kok SH; Chui CH; Lam WS; Chen J; Lau FY; Wong RS; Cheng GY; Tang WK; Teo IT; Cheung F; Cheng CH; Chan AS; Tang JC
Int J Mol Med; 2006 Dec; 18(6):1217-21. PubMed ID: 17089029
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases.
Huang W; Li J; Zhang W; Zhou Y; Xie C; Luo Y; Li Y; Wang J; Li J; Lu W
Bioorg Med Chem Lett; 2006 Apr; 16(7):1905-8. PubMed ID: 16434190
[TBL] [Abstract][Full Text] [Related]
29. Exploiting protein phosphatase inhibitors based on cantharidin analogues for cancer drug discovery.
Deng L; Dong J; Wang W
Mini Rev Med Chem; 2013 Jun; 13(8):1166-76. PubMed ID: 23373656
[TBL] [Abstract][Full Text] [Related]
30. Overview of Cantharidin and its Analogues.
Wang G; Dong J; Deng L
Curr Med Chem; 2018; 25(17):2034-2044. PubMed ID: 28413963
[TBL] [Abstract][Full Text] [Related]
31. Structural basis of serine/threonine phosphatase inhibition by the archetypal small molecules cantharidin and norcantharidin.
Bertini I; Calderone V; Fragai M; Luchinat C; Talluri E
J Med Chem; 2009 Aug; 52(15):4838-43. PubMed ID: 19601647
[TBL] [Abstract][Full Text] [Related]
32. Effects of phosphoprotein phosphatase inhibitors (phenylarsine oxide and cantharidin) on Tetrahymena.
Kovács P; Pintér M
Cell Biochem Funct; 2001 Sep; 19(3):197-205. PubMed ID: 11494309
[TBL] [Abstract][Full Text] [Related]
33. The first two cantharidin analogues displaying PP1 selectivity.
McCluskey A; Keane MA; Walkom CC; Bowyer MC; Sim AT; Young DJ; Sakoff JA
Bioorg Med Chem Lett; 2002 Feb; 12(3):391-3. PubMed ID: 11814804
[TBL] [Abstract][Full Text] [Related]
34. Mechanistic insight into a novel synthetic cantharidin analogue in a leukaemia model.
Kok SH; Chui CH; Lam WS; Chen J; Lau FY; Wong RS; Cheng GY; Tang WK; Cheng CH; Tang JC; Chan AS
Int J Mol Med; 2006 Aug; 18(2):375-9. PubMed ID: 16820948
[TBL] [Abstract][Full Text] [Related]
35. Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines.
McCluskey A; Ackland SP; Bowyer MC; Baldwin ML; Garner J; Walkom CC; Sakoff JA
Bioorg Chem; 2003 Feb; 31(1):68-79. PubMed ID: 12697169
[TBL] [Abstract][Full Text] [Related]
36. Interactions of cantharidin-like inhibitors with human protein phosphatase-5 in a Mg
Assis LC; de Castro AA; Prandi IG; Mancini DT; de Giacoppo JOS; Savedra RML; de Assis TM; Carregal JB; da Cunha EFF; Ramalho TC
J Mol Model; 2018 Oct; 24(10):303. PubMed ID: 30280322
[TBL] [Abstract][Full Text] [Related]
37. Comparison of protein phosphatase inhibition activities and mouse toxicities of microcystins.
Chen YM; Lee TH; Lee SJ; Huang HB; Huang R; Chou HN
Toxicon; 2006 Jun; 47(7):742-6. PubMed ID: 16684551
[TBL] [Abstract][Full Text] [Related]
38. Crystal structures and mutagenesis of PPP-family ser/thr protein phosphatases elucidate the selectivity of cantharidin and novel norcantharidin-based inhibitors of PP5C.
Chattopadhyay D; Swingle MR; Salter EA; Wood E; D'Arcy B; Zivanov C; Abney K; Musiyenko A; Rusin SF; Kettenbach A; Yet L; Schroeder CE; Golden JE; Dunham WH; Gingras AC; Banerjee S; Forbes D; Wierzbicki A; Honkanen RE
Biochem Pharmacol; 2016 Jun; 109():14-26. PubMed ID: 27002182
[TBL] [Abstract][Full Text] [Related]
39. Spirastrellolide A: revised structure, progress toward the relative configuration, and inhibition of protein phosphatase 2A.
Williams DE; Lapawa M; Feng X; Tarling T; Roberge M; Andersen RJ
Org Lett; 2004 Jul; 6(15):2607-10. PubMed ID: 15255702
[TBL] [Abstract][Full Text] [Related]
40. The effects of cantharidin and cantharidin derivates on tumour cells.
Liu D; Chen Z
Anticancer Agents Med Chem; 2009 May; 9(4):392-6. PubMed ID: 19442040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
